Abstract
Thrombopoietin, TPO, a 353 amino acid cytokine, is a primary regulator of platelet production that was cloned recently. A target-mediated (platelet receptors) pharmacokinetic model was developed to characterize the disposition of TPO. Receptor-mediated endocytosis was assigned as the major elimination pathway in the model. A nonspecific binding compartment was also incorporated into the model. TPO concentration vs time profiles from a published phase 1 and 2 clinical trial were used to apply this model. Noncompartmental analysis demonstrated that TPO exhibits nonlinear kinetics. The proposed model captured the concentration-time profiles relatively well. The first-order internalization rate constant was estimated as 0.1 h-1. The endogenous binding capacity was estimated as 164.0 pM. The second-order binding association constant (kon) was 0.055 h-1·pM-1 and the first-order dissociation constant (koff) was estimated as 2.5 h-1, rendering the equilibrium dissociation constant Kd as 45.5 pM. This model may be relevant to other therapeutic agents with receptor-mediated endocytotic disposition.
| Original language | English |
|---|---|
| Journal | AAPS PharmSci |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2004 |
Keywords
- Pharmacodynamic model
- Receptor-mediated drug disposition
- Thrombopoietin
Fingerprint
Dive into the research topics of 'Pharmacokinetic model of target-mediated disposition of thrombopoietin'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver